Enliven Therapeutics Files 8-K
Ticker: ELVN · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, sec-filing
TL;DR
Enliven Therapeutics filed an 8-K on 6/13/25, mostly financial statements and exhibits.
AI Summary
On June 13, 2025, Enliven Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Enliven Therapeutics is providing updated financial information and potentially disclosing other material events to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no immediate indication of significant negative events.
Key Numbers
- 001-39247 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1523849 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boulder, Colorado (location) — Principal executive offices location
- IMARA Inc. (company) — Former company name
FAQ
What specific financial statements or exhibits are included in this 8-K filing?
The provided excerpt states the filing includes 'Financial Statements and Exhibits' but does not list the specific documents.
Were there any 'Other Events' disclosed in this filing?
The filing indicates 'Other Events' as an item information, but the details of these events are not present in the excerpt.
What is the primary purpose of this 8-K filing for Enliven Therapeutics?
The primary purpose appears to be the disclosure of financial statements and exhibits, along with any other material events as required by the SEC.
When was Enliven Therapeutics incorporated?
The filing indicates the company is incorporated in Delaware.
What was the former name of Enliven Therapeutics?
The former name of Enliven Therapeutics was IMARA Inc., with a name change date of April 19, 2016.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Enliven Therapeutics, Inc. (ELVN).